Drugs Containing Excipient (Inactive Ingredient) 2,3-PENTANEDIONE

« Back to Dashboard

Generic drugs containing 2,3-PENTANEDIONE excipient

Company	Ingredient	NDC	Excipient
Devatis Inc	amoxicillin and clavulanate potassium	73043-008	2,3-PENTANEDIONE
Devatis Inc	amoxicillin and clavulanate potassium	73043-010	2,3-PENTANEDIONE

2,3-Pentanedione Market Dynamics, Pharmaceutical Excipient Status, and Financial Outlook

Last updated: November 2, 2026

2,3-Pentanedione is a small-volume diketone used primarily as a flavoring and aroma chemical, not as an established pharmaceutical excipient. Its commercial outlook is driven by food, flavor, fragrance, and specialty-chemical demand rather than prescription-drug sales. Public sources do not identify a transparent standalone market-size series, major pharmaceutical formulation franchise, Orange Book listing, or material drug-patent estate for the compound.

The main commercial constraint is regulatory and toxicological scrutiny. Flavor manufacturers and downstream users face substitution pressure from alternative diketones, natural flavor systems, and reformulated products. Pharmaceutical demand, if any, is likely to remain a niche application requiring product-specific safety and regulatory justification.

What is 2,3-pentanedione and how is it used?

2,3-Pentanedione, also called acetyl propionyl or pentane-2,3-dione, has CAS Registry Number 600-14-6. Its molecular formula is C5H8O2 and its molecular weight is 100.12 g/mol. It is a volatile diketone with buttery, creamy, and caramel-like odor characteristics.[1]

Attribute	Data
Chemical name	2,3-Pentanedione
Synonyms	Acetyl propionyl; pentane-2,3-dione
CAS number	600-14-6
Molecular formula	C5H8O2
Molecular weight	100.12 g/mol
Primary commercial role	Flavor and aroma ingredient
Pharmaceutical status	Not an established mainstream excipient
Principal demand centers	Food flavoring, beverage flavoring, fragrance, specialty chemicals
Commercial form	Bulk liquid or formulated flavor ingredient

The compound is commercially associated with flavor systems designed to provide buttery or dairy-like notes. It is also discussed in occupational-health literature because inhalation exposure to diketone flavoring chemicals has been linked to respiratory hazards in industrial settings.[2]

The distinction between a flavoring substance and a pharmaceutical excipient is important. A substance may be legally usable in food under an applicable food-flavoring framework without having broad acceptance as an inactive ingredient in oral, inhaled, topical, or parenteral medicines.

Is 2,3-pentanedione an approved pharmaceutical excipient?

2,3-Pentanedione should be classified as a niche or prospective pharmaceutical excipient rather than an established one.

It is not generally recognized as a standard tablet filler, binder, coating polymer, preservative, solubilizer, lubricant, suspending agent, or injectable excipient. Its possible pharmaceutical use would be more likely as a flavoring component in an oral liquid, chewable, orally disintegrating, or pediatric formulation.

The relevant regulatory questions are:

1. Whether the substance appears in the FDA Inactive Ingredient Database for the intended route and dosage form.
2. Whether the proposed concentration is covered by an existing precedent.
3. Whether the impurity profile and residual-solvent profile are suitable for pharmaceutical use.
4. Whether inhalation exposure creates an unacceptable risk.
5. Whether the drug sponsor can support identity, purity, stability, toxicology, and manufacturing controls.

FDA inactive-ingredient precedent is route-specific. A substance used in an oral product is not automatically cleared for inhalation, ophthalmic, injectable, or transdermal use. FDA’s excipient framework also distinguishes between historical use, compendial recognition, and sponsor-supported safety justification.[3]

For a pharmaceutical developer, 2,3-pentanedione is therefore a higher-friction choice than a commonly used flavoring or compendial excipient.

What regulatory status applies to 2,3-pentanedione?

2,3-Pentanedione is primarily regulated through chemical, food, flavoring, workplace, and product-specific frameworks. It does not have the regulatory profile of an active pharmaceutical ingredient.

Food and flavoring regulation

The compound’s commercial use is connected to flavoring applications. FEMA and food-regulatory references are relevant to intended use, specifications, and exposure assessment, but food-flavor status does not itself establish pharmaceutical acceptability.[4]

A flavor house supplying the compound to a drug manufacturer would generally need to provide:

• Certificate of analysis
• Assay and impurity specifications
• Residual-solvent data
• Elemental-impurity information
• Stability data
• Allergen and genetically modified organism statements where relevant
• Manufacturing-site and quality-system information
• Toxicological and exposure data
• Documentation for the intended dosage form and route

Occupational and inhalation exposure

Diketone flavoring chemicals have attracted regulatory attention because of respiratory exposure concerns in manufacturing environments. NIOSH has published extensive material on flavoring-related respiratory disease, including exposure to diacetyl and related compounds.[2]

This issue matters to pharmaceutical economics. A company selecting 2,3-pentanedione for an oral medicine may still face:

• Closed-transfer requirements
• Local exhaust ventilation
• Worker-exposure monitoring
• Specialized containment
• Higher occupational-health costs
• Restrictions on inhaled or aerosolized formulations

An inhalation product would face a substantially higher evidentiary burden than an oral dosage form.

What is the market size and financial trajectory for 2,3-pentanedione?

No reliable public financial series isolates 2,3-pentanedione revenue across pharmaceutical, food, flavor, and industrial applications. Supplier quotations are generally private, and public company filings typically aggregate the compound into broader flavor, fragrance, or specialty-chemical categories.

The financial trajectory is best assessed through demand drivers rather than a reported standalone market value.

Driver	Directional effect	Financial implication
Food and beverage flavor demand	Positive	Supports baseline volume
Demand for buttery and dairy-like notes	Positive	Preserves niche applications
Occupational-health scrutiny	Negative	Raises manufacturing and handling cost
Substitution by alternative flavor chemicals	Negative	Limits pricing power
Pharmaceutical adoption	Limited positive	Could improve margin but not volume materially
Inhalation-product exposure concerns	Negative	Restricts high-risk routes
Supplier qualification requirements	Negative for new entrants	Favors established specialty suppliers
Public-market visibility	Low	Limits valuation based on the compound alone

The likely financial profile is a small specialty-chemical business with limited pricing transparency and modest volume. Revenue is more likely to come from recurring formulation use in flavor systems than from large pharmaceutical contracts.

Margin profile

Pricing may be higher than commodity ketones because of:

• Small production runs
• Purity requirements
• Analytical testing
• Hazardous-material handling
• Regulatory documentation
• Customer qualification
• Packaging and transport controls

Those factors do not necessarily translate into strong margins. Buyers can often reformulate around related flavor ingredients, which limits supplier leverage.

Growth profile

The base case is low-to-moderate growth in specialty flavor applications, with flat or declining pharmaceutical relevance unless a sponsor adopts the compound in a branded oral product. The upside case involves qualification in a differentiated pediatric or orally disintegrating formulation. The downside case involves substitution triggered by toxicology, workplace controls, or customer preference for non-diketone flavor systems.

How strong is the patent estate for 2,3-pentanedione?

The compound is an old, low-molecular-weight chemical. A new composition-of-matter patent covering 2,3-pentanedione itself would generally face substantial novelty and obviousness barriers.

The commercially relevant intellectual property is more likely to involve:

• Manufacturing processes
• Purification methods
• Isomer control
• Flavor compositions
• Encapsulation systems
• Controlled-release flavor delivery
• Drug formulations containing the compound
• Specific use claims in pediatric or oral dosage forms

A standalone pharmaceutical patent estate for 2,3-pentanedione is not evident from its conventional regulatory and commercial profile. Any valuable patent position would probably attach to a formulation or delivery system rather than to the molecule.

IP category	Expected relevance
Composition-of-matter patent	Low
Synthetic process patent	Moderate
Purification patent	Moderate
Flavor composition patent	Moderate
Pharmaceutical formulation patent	Potentially material but product-specific
Inhalation-use patent	Legally possible, commercially constrained
Trade secret protection	Relevant for process and quality control
Trademark protection	Relevant to finished products, not the molecule

Does 2,3-pentanedione have Orange Book or Paragraph IV exposure?

2,3-Pentanedione is not an FDA-approved drug active ingredient and does not ordinarily generate an Orange Book or Paragraph IV litigation pathway.

The Orange Book applies to FDA-approved drug products and associated listed patents. Paragraph IV certifications apply to abbreviated new drug applications challenging listed patents for reference drugs. A flavoring or excipient supplier would not normally face Paragraph IV litigation over the compound itself.[5]

Relevant pharmaceutical disputes would more likely concern:

• A finished drug formulation
• A delivery system
• A method of use
• Trade secrets
• Supplier qualification
• Contract manufacturing
• Product-liability claims
• Regulatory compliance

No material settlement or generic-entry litigation pattern is associated with 2,3-pentanedione as a standalone pharmaceutical ingredient.

What formulation opportunities exist for 2,3-pentanedione?

The strongest potential pharmaceutical use is in oral products where taste masking or patient acceptability affects adherence.

Potentially relevant dosage forms

• Oral solutions
• Oral suspensions
• Syrups
• Chewable tablets
• Orally disintegrating tablets
• Pediatric granules
• Buccal products, subject to exposure assessment

The compound is less attractive for:

• Inhalation products
• Nebulized products
• Injectable products
• Ophthalmic products
• High-exposure transdermal systems

A formulation containing 2,3-pentanedione would need to control volatility, migration, oxidation, and flavor intensity. Packaging selection could include high-barrier containers, low-permeability liners, and tight closure systems. Compatibility with active ingredients, polymers, preservatives, and container components would require testing.

Flavor intensity also creates a narrow operating window. Excess concentration can produce off-notes, instability, or unacceptable exposure, while insufficient concentration may not improve palatability.

How does 2,3-pentanedione compare with competing flavor ingredients?

The primary alternatives are other diketones, short-chain carbonyl compounds, natural flavor extracts, and engineered flavor systems.

Alternative	Relative commercial role	Key advantage	Key limitation
Acetoin	Butter and cream flavor	Broad flavor utility	May require blending
Diacetyl	Strong buttery note	High sensory potency	Significant respiratory-health scrutiny
2,3-Hexanedione	Flavor and aroma use	Distinct profile	Regulatory and toxicology review
Natural dairy flavors	Clean-label positioning	Consumer acceptance	Higher cost and variable composition
Encapsulated flavor systems	Controlled release	Better stability and masking	Higher formulation complexity
Synthetic flavor blends	Tunable sensory profile	Flexible cost and performance	More complex qualification

2,3-Pentanedione can occupy a middle position between strong synthetic diketones and more expensive natural or encapsulated systems. Its commercial viability depends on sensory performance, toxicological profile, customer specifications, and the cost of switching.

Which companies and supply-chain participants matter?

The market is fragmented across flavor houses, aroma-chemical suppliers, custom-synthesis companies, and chemical distributors. Public financial reporting rarely identifies 2,3-pentanedione sales by name.

The most important competitive variables are:

• Consistent batch purity
• Reliable supply
• Regulatory documentation
• Low residual impurities
• Controlled odor profile
• Packaging integrity
• Occupational exposure controls
• Ability to support customer audits
• Capacity to produce pharmaceutical-grade material

Large flavor companies may use the ingredient within proprietary blends without disclosing the compound in public filings. Specialty chemical distributors may offer catalog or custom-sourced material, but catalog availability does not establish pharmaceutical qualification.

What generic-entry and biosimilar risks exist?

There is no conventional generic-entry or biosimilar market for 2,3-pentanedione.

The relevant competitive risk is ingredient substitution. A customer can replace the compound with another flavoring, a natural extract, a blended system, or an encapsulated delivery technology. Switching costs rise when the compound is embedded in a validated drug formulation, but those costs are formulation-specific and do not create molecule-level exclusivity.

Biosimilar risk is not applicable because 2,3-pentanedione is a small chemical, not a biologic.

What manufacturing and intellectual-property barriers affect supply?

Manufacturing barriers are moderate, not prohibitive. The compound is a small synthetic molecule, but pharmaceutical adoption would require tighter controls than ordinary flavor use.

Key barriers include:

• Control of reaction selectivity
• Management of volatile diketone intermediates
• Removal of related carbonyl impurities
• Batch-to-batch odor consistency
• Stability under storage
• Containment and worker protection
• Validated analytical methods
• Documentation suitable for regulated customers

The strongest defensibility is likely operational rather than patent-based. A supplier with validated production, regulatory files, reliable analytical data, and customer approvals may retain accounts even when the underlying molecule is not patent-protected.

What is the commercial outlook for 2,3-pentanedione?

The base-case outlook is a stable niche flavoring market with limited direct pharmaceutical expansion. Financial performance should track broader flavor-and-fragrance demand, customer reformulation activity, and regulatory treatment of diketone exposure.

The most likely scenarios are:

Scenario	Commercial outcome
Base case	Stable specialty demand; modest price competition
Upside case	Qualification in oral pharmaceutical or pediatric formulations
Downside case	Substitution after toxicology, workplace, or customer-policy pressure
Severe downside case	Restrictions on specific uses or loss of major flavor applications

A pharmaceutical formulation could generate attractive unit economics, but it would not necessarily create a large market. The principal value would come from qualification, switching costs, and recurring supply rather than from patent exclusivity.

Key Takeaways

• 2,3-Pentanedione is primarily a flavor and aroma chemical, not a mainstream pharmaceutical excipient.
• Its pharmaceutical opportunity is concentrated in oral taste-masking applications.
• No standalone public market-size or revenue series reliably measures the compound.
• The financial outlook is driven by specialty flavor demand, substitution risk, and regulatory scrutiny.
• Orange Book listings, Paragraph IV challenges, biosimilar competition, and conventional generic-entry litigation are not material at the molecule level.
• Patent value is more likely to arise from formulations, delivery systems, or manufacturing processes than from the chemical itself.
• Occupational and inhalation exposure concerns are the principal constraints on broader adoption.
• Supplier qualification, purity control, documentation, and containment are more important commercial barriers than composition-of-matter patents.

FAQs

Is 2,3-pentanedione used in tablets?

It could be used as a flavoring component in chewable or orally disintegrating tablets, but it is not a standard tablet excipient. Use would require formulation-specific safety and regulatory support.

Is 2,3-pentanedione the same as diacetyl?

No. Diacetyl is 2,3-butanedione, while 2,3-pentanedione has one additional carbon atom. Both are diketone flavor chemicals, but they have different chemical identities and regulatory assessments.

Can 2,3-pentanedione be used in inhaled medicines?

Inhaled use would face a high regulatory and toxicological burden because pulmonary exposure is more direct than oral exposure. It is commercially less attractive for inhalation products than for oral flavor applications.

Does 2,3-pentanedione have a pharmaceutical monograph?

It is not generally treated as a mainstream USP-NF pharmaceutical excipient monograph substance. Pharmaceutical users would typically rely on supplier specifications and product-specific quality and safety documentation.

Is 2,3-pentanedione a good pharmaceutical investment target?

On a standalone basis, it is unlikely to support a large pharmaceutical investment thesis. Its value is stronger as part of a specialty flavor platform, regulated excipient portfolio, formulation technology, or supply business with validated customers.

References

1. National Center for Biotechnology Information. (n.d.). PubChem compound summary for 2,3-pentanedione. PubChem. https://pubchem.ncbi.nlm.nih.gov/

2. National Institute for Occupational Safety and Health. (2016). Criteria for a recommended standard: Occupational exposure to diacetyl and 2,3-pentanedione. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/niosh/

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. Flavor and Extract Manufacturers Association. (n.d.). Flavor ingredient safety and FEMA GRAS information. https://www.femaflavor.org/

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book